Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABBV 706 (Primary) ; Budigalimab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary)
  • Indications Astrocytoma; Brain metastases; Carcinoid tumour; Gastrointestinal cancer; Glioblastoma; Large cell carcinoma; Neuroendocrine carcinoma; Oligodendroglioma; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie

    • Most Recent Events

    • 11 Mar 2025 Planned End Date changed from 1 May 2027 to 1 Nov 2027.
    • 11 Mar 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Nov 2027.
    • 22 Jan 2025 Planned End Date changed from 17 May 2027 to 1 May 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top